热门资讯> 正文
由于卢平提交仿制药neffy申请，ARS Pharma股价下跌9%
2025-08-30 00:04
- ARS Pharmaceuticals (NASDAQ:SPRY) is down ~9% in Friday trading after disclosing that Indian drugmaker Lupin has filed an ANDA with the U.S. FDA for a generic version of neffy, an epinephrine nasal spray.
- An SEC filing states that Lupin is challenging several neffy patents as invalid, including one covering composition of matter.
- Currently, those patents are not slated to expire until February 2039.
- ARS launched neffy in the U.S. in September 2024. In Q2 of this year, the product had U.S. sales of $12.8M.
- "The Company intends to vigorously defend its intellectual property rights relating to neffy and promptly file a patent infringement suit against Lupin, seeking, among other remedies, a permanent injunction to prevent Lupin from introducing a generic version of neffy that would infringe the Patents," ARS said in the SEC filing.
More on ARS Pharmaceuticals
- ARS Pharmaceuticals, Inc. (SPRY) Q2 2025 Earnings Call Transcript
- ARS Pharmaceuticals: High Risk High Reward Rollout Of No Needle Epinephrine
- ARS Pharmaceuticals: 'Betting On The Come'
- ARS Pharmaceuticals signals continued neffy momentum with 180% prescription surge and global expansion targets
- ARS Pharmaceuticals GAAP EPS of -$0.46 beats by $0.01, revenue of $15.72M beats by $1.94M
推荐文章
美股机会日报 | 金价再创新高！黄金股普涨，哈莫尼黄金涨超4%；百度涨超7%
新股暗盘 | 大行科工大涨100%！中签一手赚4950港元
新股申购 | “全球激光雷达龙头”禾赛-W正在招股！一手入场费4605.99港元
华盛早报 | 大动作！特斯拉AI芯片+人型机器人，马斯克发声！禾赛今日招股；恒指成份股调整今日生效
港股周报丨疯狂扫货！北水年内净流入港股超万亿港元；创新药概念狂飙，三生制药周涨超22%
美股机会日报 | 8月非农大幅低于预期！纳指期货短线拉涨约0.7%；特斯拉盘前涨近2%
一周财经日历 | 事关降息！中美5月CPI、PPI重磅出炉！新股“超购王”大行科工下周上市
高盛：降新鸿基地产目标价至96港元 评级“买入”
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
